1. Chemical conjugation of ΔF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions
- Author
-
Giulio Cabrini, Marco Colombatti, Luigi Cattel, Franco Dosio, Federica Quiri, Caroline Norez, Anna Tamanini, Paolo Rizzotti, Erika Barison, Matteo Pasetto, Cristina Anselmi, Maria Cristina Dechecchi, Institut de physiologie et biologie cellulaires (IPBC), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Laboratory of Molecular Pathology, University Hospital of Verona, Department of Pathology, University of Verona (UNIVR), Department of Science and Technology of Medicines, University of Turin, and This work was partially supported by grants from Fondazione Cariverona (Progetti Bando 2004), by MIUR (PRIN 2005), and by Italian Cystic Fibrosis Research Foundation (#1/2006) (to M. Colombatti), and Fondazione Cariverona-Bando 2005-Malattie rare e della povertà (to G. Cabrini).
- Subjects
Protein Folding ,Physiology ,medicine.disease_cause ,Cystic fibrosis ,Guanidines ,0302 clinical medicine ,Fibrosis ,Disulfides ,Intracellular activation ,0303 health sciences ,Mutation ,Drug Carriers ,biology ,respiratory system ,Human serum albumin ,Transmembrane protein ,Cystic fibrosis transmembrane conductance regulator ,Cell biology ,Transport protein ,Cross-Linking Reagents ,Biochemistry ,030220 oncology & carcinogenesis ,Oxidoreductases ,Immunosuppressive Agents ,medicine.drug ,Pulmonary and Respiratory Medicine ,conjugates ,Correctors ,congenital, hereditary, and neonatal diseases and abnormalities ,Serum albumin ,Cell Line ,03 medical and health sciences ,Physiology (medical) ,medicine ,[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Humans ,Point Mutation ,chaperones ,Serum Albumin ,030304 developmental biology ,Correctors, Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Intracellular activation, Transporter protein ,Cell Biology ,medicine.disease ,cystic fibrosis ,transporter protein ,intracellular activation ,Transporter protein ,digestive system diseases ,respiratory tract diseases ,biology.protein ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Molecular Chaperones - Abstract
(IF : 4,214); International audience; The most common mutation of the cystic fibrosis (CF) gene, the deletion of Phe508, encodes a protein (DeltaF508-CFTR) that fails to fold properly, thus mutated DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) is recognized and degraded via the ubiquitin-proteasome endoplasmic reticulum-associated degradation pathway. Chemical and pharmacological chaperones and ligand-induced transport open options for designing specific drugs to control protein (mis)folding or transport. A class of compounds that has been proposed as having potential utility in DeltaF508-CFTR is that which targets the molecular chaperone and proteasome systems. In this study, we have selected deoxyspergualin (DSG) as a reference molecule for this class of compounds and for ease of cross-linking to human serum albumin (HSA) as a protein transporter. Chemical cross-linking of DSG to HSA via a disulfide-based cross-linker and its administration to cells carrying DeltaF508-CFTR resulted in a greater enhancement of DeltaF508-CFTR function than when free DSG was used. Function of the selenium-dependent oxidoreductase system was required to allow intracellular activation of HSA-DSG conjugates. The principle that carrier proteins can deliver pharmacological chaperones to cells leading to correction of defective CFTR functions is therefore proven and warrants further investigations.
- Published
- 2008
- Full Text
- View/download PDF